Omega-3和前列腺癌的恩怨情仇

从2015年夏季开始,整个Omega-3产业开始应对来自各方的批评之声,这些质疑来自于一篇学术文章:《Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial》(选择试验中血浆磷脂酸与前列腺癌症风险).该文章的研究结果表明人体内Omega-3脂肪酸与前列腺癌症存在正相关.

对Gender-and Smoking-Related Bladder Cancer Risk一文的评析

从流行病学研究的原理及方法学角度出发,笔者对Castelao等的Gender-and Smoking-Related Bladder Cancer Risk[Journal of the National Cancer Institute,2001,93∶538-545]一文进行分析.

Overview of breast cancer prevention: what's the next?

Breast cancer is the leading cause of death among women at the ages of 20-59 years[1].The incidence of breast cancer in Asia is also shown to be increasing recently, especially in the more affluent cities, and the peak incidence of breast cancer is at the age of 45-50 years[2].Breast cancer prevention has started from secondary prevention strategy of early detection of the disease with different modalities in Asia[3-5] despite the absence of unified nationwide screening program.There are a lot of discussion about the benefits and harms of breast cancer screening[6-8] and still a lot of controversial issues such as stratification of breast cancer risk, choice of screening modalities, ways of information dissemination, different culturo-religious beliefs, and various levels of medical resources, especially in Asia, remain unresolved.In no doubt, a cost-effective prevention method should be more widely accepted.

While we studied pharmacokinetics of SM-12502 which was under development as an anti-PAF agent, we found three subjects showing a slow metabolic phenotype in its pharmacokinetics.

Muscular dystrophies (MD) comprise a heterogeneous group of hereditary myopathic diseases. In this group, myotonic MD is associated with an increased cancer risk. However, the cancer risk in other types of MD is unclear. To address this gap in knowledge, we assessed data obtained from the Taiwan Health Insurance Program database. A total of 1,272 patients with MD diagnosed between 1997 and 2009 were enrol ed. They were fol owed up for cancer during the same period by record linkage with the cancer certification in Taiwan. Age- and sex-standardized incidence ratios (SIRs) of overall and site-specific cancers were calculated. For congenital and progressive hereditary MD, there were 685 and 505 cases (males:69.5%and 80.6%), the median ages at diagnosis were 16 and 13 years, and the mean fol ow-up durations were 7.12 and 5.06 years, respectively. In addition, cancers were developed in 10 patients with congenital MD and 3 patients with progressive hereditary MD. Female MD patients exhibited an increased cancer risk, yielding an SIR of 3.37 [95%confidence interval (CI)=1.38-8.25] in congenital MD and 2.95 (95% CI = 0.95-9.19) in hereditary progressive MD. Site-specific cancer SIRs were not powered to be significantly different. In conclusion, genetic defects in hereditary MD may increase cancer risks in females and a sex difference should be further investigated.